MARKET

SIBN

SIBN

SI-BONE
NASDAQ

Real-time Quotes | Nasdaq Last Sale

22.80
-0.18
-0.78%
After Hours: 22.80 0 0.00% 16:00 10/20 EDT
OPEN
23.21
PREV CLOSE
22.98
HIGH
23.49
LOW
22.50
VOLUME
380.68K
TURNOVER
--
52 WEEK HIGH
26.41
52 WEEK LOW
7.20
MARKET CAP
720.76M
P/E (TTM)
-13.2128
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
SI-BONE To Report Third Quarter 2020 Financial Results on November 2, 2020
SANTA CLARA, Calif., Oct. 19, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the third quarter of 2020 after market close on Monday, November 2, 2020. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing (866) 470-1968 for domestic callers or (409) 217-8248 for international callers, using conference ID: 6728555. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event. About SI-BONESI-BONE is a medical device company that pioneered minimally invasive surgery of the SI joint with the iFuse Implant System. Studies have shown that the SI joint can be a source of pain in 15% to 30% of chronic low back pain. The iFuse Implant™, commercially available since 2009, is the only SI joint fusion device supported by multiple prospective clinical studies, including two RCTs, showing improved pain, patient function and quality of life resulting from treatment. There are over 80 peer-reviewed publications demonstrating the safety, durable effectiveness, and biomechanical and economic benefits unique to the iFuse Implant (www.si-bone.com/results). This body of evidence has enabled multiple government and private insurance payors to establish coverage of the SI joint fusion procedure exclusively when performed with the iFuse Implant System.The iFuse Implant System is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months. The iFuse Implant System is also intended for sacroiliac fusion to augment stabilization and immobilization of the sacroiliac joint in skeletally mature patients undergoing sacropelvic fixation as part of a lumbar or thoracolumbar fusion. As well, the iFuse Implant System is intended for sacroiliac fusion in acute, non-acute, and non-traumatic fractures involving the sacroiliac joint. There are potential risks associated with the iFuse Implant System. It may not be appropriate for all patients and all patients may not benefit.For additional information on the company or the products including risks and benefits, please visit www.si-bone.com. SI-BONE and iFuse Implant System are registered trademarks of SI-BONE, Inc. ©2020 SI-BONE, Inc. All Rights Reserved. 10857.1019.2020Investor Contact: Matt Bacso, CFA investors@SI-BONE.com Media Contact: Joe Powers jpowers@si-bone.com
GlobeNewswire · 1d ago
The Daily Biotech Pulse: Vertex Pulls Plug On Protein Deficiency Drug, FDA Nod For Regeneron's Ebola Treatment, Can Fite Issues Psoriasis Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 14)
Benzinga · 5d ago
SI-BONE slips 7% after pricing equity offering at $22
SI-BONE (SIBN) has priced its public offering of 3,190,053 shares of common stock, including 3M company's shares and 190,053 offered by a selling stockholder. common shares at $22.00/share, for expected gross
Seekingalpha · 6d ago
SI-BONE Announces Launch of Public Offering of Common Stock
SANTA CLARA, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN) (“SI-BONE”), a Silicon Valley-based medical device company focused on the development of implantable devices used in the surgical treatment of the sacropelvic anatomy, today announced that it has commenced an underwritten public offering of 3,190,053 shares of its common stock. In addition, SI-BONE expects to grant the underwriters a 30-day option to purchase up to an additional 478,507 shares of common stock on the same terms and conditions. Of the shares of common stock being offered, 3,000,000 shares are being offered by SI-BONE and 190,053 shares are being offered by a selling stockholder. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. Morgan Stanley and BofA Securities are acting as joint book-running managers. Cantor Fitzgerald & Co., JMP Securities LLC and Needham & Company are acting as co-managers.A shelf registration statement relating to the shares being sold in this offering was filed with the U.S. Securities and Exchange Commission on December 26, 2019, and was declared effective on January 2, 2020. The offering will be made only by means of a prospectus supplement and accompanying prospectus. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available for free on the SEC’s website located at https://www.sec.gov. When available, electronic copies of the preliminary prospectus supplement and accompanying prospectus relating to the proposed public offering may be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; or from BofA Securities, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attn: Prospectus Department, or email at dg.prospectus_requests@bofa.com.This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.About SI-BONESI-BONE is a medical device company that pioneered minimally invasive surgery of the SI joint with the iFuse Implant System.Forward-Looking StatementsThis press release contains forward-looking statements, including statements relating to SI-BONE’s expectations regarding the proposed public offering. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. SI-BONE cautions investors not to place undue reliance on the forward-looking statements contained in this release. These risks and uncertainties include, without limitation, risks and uncertainties related to market conditions, the risk that the proposed public offering will not be consummated on the terms or in the amounts contemplated or otherwise, and the satisfaction of customary closing conditions related to the proposed public offering. Risks and uncertainties relating to SI-BONE and its business can be found in the “Risk Factors” section of SI-BONE’s Form 10-Q for the quarter ended June 30, 2020, filed with the SEC on August 4, 2020, and in the preliminary prospectus contained in the registration statement related to the proposed public offering filed with the SEC on October 14, 2020. SI-BONE undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in SI-BONE’s expectations, except as required by law.Investor Contact: Matt Bacso, CFA investors@SI-BONE.comMedia Contact: Joe Powers jpowers@si-bone.com
GlobeNewswire · 6d ago
SI-BONE readies equity offering
SI-BONE (SIBN) commences an underwritten public offering of 3,190,053 common shares.Underwriters have a 30-day option to purchase up to an additional 478,507 common shares.Of the shares of common stock being
Seekingalpha · 6d ago
SI-BONE Announces Offering Of 3.19M Shares
SI-BONE Announces Launch of Public Offering of Common Stock SANTA CLARA, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN) ("SI-BONE"), a Silicon Valley-based medical device company focused
Benzinga · 6d ago
The Daily Biotech Pulse: FDA Panel Review For Alkermes, Axovant Gets Rare Pediatric Disease Designation, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 8)
Benzinga · 10/09 11:20
SI-BONE provides Q3 and full-year guidance
SI-BONE (SIBN) preliminary and unaudited revenue for Q3 is expected to be in the range of $20.1M-20.4M, reflecting growth of 24%-26% compared to the prior year period.Q3 U.S. revenue expected $18.7M-18.9M,
Seekingalpha · 10/08 12:19
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SIBN. Analyze the recent business situations of SI-BONE through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SIBN stock price target is 27.14 with a high estimate of 30.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 108
Institutional Holdings: 20.43M
% Owned: 70.81%
Shares Outstanding: 31.61M
TypeInstitutionsShares
Increased
41
2.02M
New
25
-103.88K
Decreased
18
1.53M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-1.70%
Healthcare Equipment & Supplies
-0.72%
Key Executives
Chairman/President/Chief Executive Officer/Director
Jeffrey Dunn
Chief Financial Officer/Chief Operating Officer
Laura Francis
Chief Compliance Officer/General Counsel
Michael Pisetsky
Other
Anthony Recupero
Lead Director/Independent Director
Timothy Davis
Independent Director
Mark Foley
Independent Director
John Freund
Director
Jeri Hilleman
Independent Director
Jeryl Hilleman
Independent Director
Gregory Hinckley
Independent Director
Karen Licitra
Independent Director
Keith Valentine
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SIBN
SI-BONE, Inc. is focused on development of medical devices. The Company is engaged in the development, manufacture and commercialization of minimally invasive surgical devices for the treatment of patients with low back symptoms related to certain sacroiliac (SI) joint disorders. The Company offers iFuse Implant System, which provides a minimally invasive surgical solution to fuse the SI joint using patented triangular titanium implants that create an interference fit within the ilium and sacrum. The triangular implant shape, combined with the press fit insertion, is designed to provide fixation by minimizing rotational motion. The implants has a porous surface that provide an environment for bone ongrowth and ingrowth, facilitating long-term fusion of the joint. The iFuse Implant System is intended for sacroiliac fusion for conditions, including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of SI-Bone Inc stock information, including NASDAQ:SIBN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SIBN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SIBN stock methods without spending real money on the virtual paper trading platform.